Geode Capital Management LLC Buys 21,854 Shares of Tetraphase Pharmaceuticals Inc (TTPH)

Geode Capital Management LLC boosted its stake in shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) by 4.1% in the 4th quarter, Holdings Channel reports. The firm owned 551,837 shares of the biopharmaceutical company’s stock after buying an additional 21,854 shares during the quarter. Geode Capital Management LLC’s holdings in Tetraphase Pharmaceuticals were worth $623,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of TTPH. Gamco Investors INC. ET AL boosted its position in Tetraphase Pharmaceuticals by 42.9% during the fourth quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 15,000 shares during the last quarter. SG Americas Securities LLC acquired a new position in Tetraphase Pharmaceuticals during the fourth quarter valued at approximately $69,000. Rhumbline Advisers boosted its position in Tetraphase Pharmaceuticals by 40.6% during the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 21,089 shares during the last quarter. Alambic Investment Management L.P. boosted its position in Tetraphase Pharmaceuticals by 31.0% during the fourth quarter. Alambic Investment Management L.P. now owns 114,874 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 27,170 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Tetraphase Pharmaceuticals during the third quarter valued at approximately $927,000. 43.39% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:TTPH opened at $0.98 on Friday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 7.73 and a current ratio of 7.28. The company has a market capitalization of $54.26 million, a price-to-earnings ratio of -0.72 and a beta of 2.85. Tetraphase Pharmaceuticals Inc has a 12-month low of $0.95 and a 12-month high of $4.49.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. The firm had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.93 million. Tetraphase Pharmaceuticals had a negative return on equity of 80.01% and a negative net margin of 383.19%. Equities research analysts predict that Tetraphase Pharmaceuticals Inc will post -1.52 EPS for the current fiscal year.

Several research analysts recently commented on TTPH shares. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. ValuEngine cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Gabelli cut Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.40 price target for the company. in a research report on Friday, March 15th. Piper Jaffray Companies reduced their price target on Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating for the company in a research report on Friday, March 15th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Monday, May 6th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $4.08.

ILLEGAL ACTIVITY WARNING: This article was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/12/geode-capital-management-llc-buys-21854-shares-of-tetraphase-pharmaceuticals-inc-ttph.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Read More: Hedge Funds Explained

Want to see what other hedge funds are holding TTPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH).

Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.